Author/Authors :
Olivier Corminboeuf، نويسنده , , Guillaume Dunet، نويسنده , , Mehdi Hafsi، نويسنده , , Julien Grimont، نويسنده , , Corinna Grisostomi، نويسنده , , Solange Meyer، نويسنده , , Christoph Binkert، نويسنده , , Daniel Bur، نويسنده , , Andrew Jones، نويسنده , , Lars Prade، نويسنده , , Reto Brun، نويسنده , , Christoph Boss، نويسنده ,
Abstract :
In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results, targeting Plasmepsin II, a Plasmodium falciparum aspartic protease active in hemoglobin degradation, a parasite specific catabolic pathway. The results show that the new structural class is not only inhibiting PMII in vitro but is also active in a P. falciparum infected human red blood cell assay.
